A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands

M. Raphael Pfeffer*, Yoav Talmi, Raphael Catane, Zvi Symon, Ady Yosepovitch, Mark Levitt

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

156 Scopus citations

Abstract

Adenoid cystic carcinoma of the salivary glands is characterized by a poor response to chemotherapy. Most cases of adenoid cystic carcinoma express the c-kit protein. Imatinib mesylate (Gleevec) inhibits several protein-tyrosine kinases, including c-kit. We therefore hypothesized that Imatinib may be an effective drug in patients with locally advanced or metastatic adenoid cystic carcinoma and conducted a phase 2 trial in order to study this. Patients with locally advanced or metastatic adenoid cystic carcinoma and c-kit positive tumours were eligible. Fourteen patients were screened and 10 patients (71%) with c-kit positive tumours entered the study. Treatment was begun at a dose of Imatinib of 400 mg/day. Dose escalation was allowed in the absence of toxicity. The dose was increased to 600 mg/d in three patients and 800 mg/d in one patient. Three patients required dose reduction to 300 mg/d, due to grade 3 toxicity. No grade 4 toxicity was seen. No objective responses were seen. Two patients (20%) exhibited stable disease for 11 and 14 months, respectively. All other patients stopped treatment after 2-14 (median 6) months due to progressive disease. Imatinib has no major effect on advanced adenoid cystic carcinoma of the head and neck.

Original languageEnglish
Pages (from-to)33-36
Number of pages4
JournalOral Oncology
Volume43
Issue number1
DOIs
StatePublished - Jan 2007

Keywords

  • Adenoid cystic
  • Carcinoma
  • Imatinib
  • Salivary glands
  • Therapy

Fingerprint

Dive into the research topics of 'A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands'. Together they form a unique fingerprint.

Cite this